Glycosylation is among the most complex post-translational modifications with an extremely high level of diversity that has made it refractory to high-throughput analyses. Despite its resistance to high-throughput techniques, glycosylation is important in many critical cellular processes that necessitate a productive approach to their analysis. To facilitate studies in glycosylation, we developed a high-throughput lectin microarray for defining mammalian cell surface glycan signatures. Using the lectin microarray we established a binary analysis of cell binding and hierarchical organization of 24 mammalian cell lines. The array was also used to document changes in cell surface glycosylation during cell development and differentiation of primary murine immune system cells. To establish the biological and clinical importance of glycan signatures, the lectin microarray was applied in two systems. First, we analyzed the cell surface glycan signatures and were able to predict mannose-dependent tropism using a model pathogen. Second, we used the glycan signatures to identify novel lectin biomarkers for cancer 
stem-like cells in a murine model. Thus, lectin microarrays are an effective tool for analyzing diverse cell processes including cell development and differentiation, cell-cell communication, pathogen-host recognition, and cell surface biomarker identification.
Introduction
The surfaces of all vertebrate cells are distinguished by a dense and diverse array of cell surface glycans, the "glycocalyx". Glycosylation is a major form of posttranslational modification (Kukuruzinska et al. 1987 ; Lehle et al. 2006) and variation in glycosylation is associated with cell differentiation and malignant transformation (Hakomori 2002; Hakomori 1985; Dwek et al. 2001 ; Dennis et al. 1999) . This makes it a potentially valuable diagnostic indicator of cellular diversity and differentiation (Brooks and Leathem 1991) . Specific surface glycosylation patterns are characteristic features of certain cell types, such as embryonic stem cells (Muramatsu 2002) , and whole organs, such as the kidney and ABO blood group antigens (Morgan and Watkins 2000; Palcic et al. 1990 ). Recently, a growing body of evidence indicates that changes in the expression of sugar-bearing molecules may actively direct a variety of cell biological processes (Haltiwanger and Lowe 2004; Van Dyken et al. 2007 ). The combinatorial possibilities inherent in glycan structure far exceed DNA-and peptide-based structural diversity (Gabius et al. 2004 ). This enormous structural diversity coupled with accessibility at the cell surface makes glycosylation an important mechanism for regulating cellular interactions with the environment, neighboring cells, and pathogens.
The same structural diversity that provides a cell's surface glycome with biological significance also makes it refractory to rapid detailed analysis. Nevertheless, lectins, which are glycan binding 4 proteins, have long been used in techniques such as blots, flow cytometry, and immunohistochemistry to characterize serum or cells by focusing on individual glycans (Ferguson et al. 2005; Reisner et al. 1976; Varki 1999; Macartney 1987; Yuan et al. 1986 ). Lectin-based approaches are particularly advantageous because of their ability to discriminate sugar isomers (Hirabayashi 2004) . Given the commercial availability of a large number of lectins with a variety of glycan specificities, their use in microarrays to provide more accurate and detailed "cell surface glycan signatures" is an inviting alternative to structural analyses, the latter of which are not amenable to rapid or high-throughput approaches. Although lectin microarrays have been used to profile glycoproteins and cell lysates (Ebe et al. 2006; Lee et al. 2006b; Kuno et al. 2005; Pilobello et al. 2007) , their use for profiling live cells have been limited to proof-of-principle (Lee et al. 2006a; Zheng et al. 2005 ) studies. For example, lectin microarrays accurately and predictably distinguish between glycosylation-defective CHO mutants (Tateno et al. 2007) , and Hsu et al. used a 21-lectin microarray to distinguish O-antigens on lipopolysaccharides (LPS) of bacterial cell surfaces (Hsu et al. 2006) . Here, we demonstrate that a lectin microarray can be used to reveal biologically and clinically relevant cell surface glycan signatures, and report the application of this technology to immune cell differentiation, pathogen-cell tropism, and cancer stem cell identification. These findings show that lectin microarrays are an excellent tool both for prediction of glycan based cell-cell interactions, and identification of novel cell surface biomarkers.
Results

Surface glycan signatures defined by lectin microarrays in mammalian cells
To probe the accessible surface glycans or cell surface glycan signatures, we collected a panel of 94 lectins with an extensive range of specificities (Supplementary Table I Fig. 1A ). Individual cells captured on 120-micron spots could be readily distinguished by fluorescent microscopy, indicating that their interactions with lectins immobilized on solid surfaces was due to the binding of intact cells (Supplementary Fig. 1A, inset) . To determine if the binding signals observed resulted from direct interactions between the lectins and glycans on the cell surfaces, we tested the specificity using the simple sugar inhibitors, α-methyl-mannoside or the disaccharide lactose (Galβ1−4Glc). Labeled HeLa and 293 cells were incubated on lectin microarrays in the presence or absence of either α-methyl-mannoside (200 mM) or lactose (200 mM). Binding of both cell lines to the lectins LCA, specific for mannose, and TKA, specific for lactose or terminal galactose, were inhibited only by their respective glycan ligands (Supplementary Fig. 1B) . Cell binding to SNA, which is not specific for either mannose or lactose, was unaffected by the presence of either soluble glycans. The lectin array demonstrates glycan specific cell binding and is useful in probing accessible cell surface glycans.
A lectin binding signature for mammalian cell lines
To demonstrate the capability of the lectin microarrays to distinguish among the cell surface glycan repertoires of mammalian cells, 24 different types of human cell lines were tested (Supplementary Table II) . To account for significant variations in size, morphology, and labeling efficiency of cells, absolute quantification and cross-cell line normalization was not performed, but instead, a binary analysis was used to process the data (Supplementary Figs. 2 & 3). Each lectin was designated either bound or unbound to every cell line using a two-step method (see Materials and Methods for details). Using this analysis, a cell binding map was generated (Fig. 1A ). Significant differences in lectin binding patterns were observed among different cell lines. For example, less than 20 lectins could capture the hESC, Caco-2, D407, and U937 cells, while more than 50 lectins captured the TAg, 293, K1106, and MCF7 cells. These data indicate that the accessible cell surface glycans of mammalian cells varies significantly from one cell type to another. Accordingly, the cell lines were clustered into two major groups. Some related cell types clustered tightly, for example, the retina-derived cell lines, ARPE19, WER1, and Y79. In contrast, three breast cancer cell lines, For those lectins that showed no binding activity to the tested cells, it is possible that they either have relatively low affinity or are of low quality.
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To further validate the lectin binding profile, we analyzed representative lectin-cell binding using flow cytometry. Lectins that were selected were representative of four categories such as: Jacalin bound to all cell types; RPA bound to most cell types; HHA and UEA-I, bound to only a few cell types; UEA-II, bound to no cell types (Fig. 1B) . The flow cytometry data for each lectin correlated well with microarray binding (compare Fig. 1B with respective insets) . High cell binding on the microarray was reflected as a large shift in the mean channel fluorescence (MCF) by flow cytometry, whereas low cell binding to the microarray was verified by negligible shifts in MCF over unstained control.
The analysis also showed that there is additional information that we are currently not harvesting in the binary lectin binding profile. For example, HHA lectin had intermediate binding capacity in the microarray analysis (Fig. 1B, inset) . In our ranking system this appeared only as a positive (Fig. 1B) . As microarray technology matures, one could extract additional information through quantitative analysis of lectin binding.
A lectin binding signature for differentiating lymphocytes
The lectin microarray discriminated between closely related primary murine cells and revealed glycosylation changes in differentiating immune system cells (Rudd et al. 1999) . We probed the lectin microarrays with naïve and activated B cells, thymocytes (immature T cells that are lineage committed but not fully differentiated), naïve, and activated T cells ( Fig. 2A) . Certain differential patterns of lectin binding to immune B and T cells were observed (Fig. 2) .
Twelve of the 17 surface lectin binding motifs ( Supplementary Fig. 4 ) for lectin binding in immature, mature, and activated T lymphocytes were identical (data not shown). Despite the similarities, there are also clear differences among the lymphocyte populations. The largest segment of differentially bound lectins, such as the Gal-GalNAc specific BPL, bound all cells with the exception of naïve T cells ( Fig. 2A) . Lectins which captured thymocytes and activated T cells but not naïve T cells have relatively narrow sugar specificities usually consisting of Gal, GalNAc, and GlcNAc. Differential recognition of Gal-GalNAc, the core-1 O-glycan, reflects known changes in glycan expression when transitioning from immature thymocyte cells to naïve T cells to activated T cells (Daniels et al. 2002; Daniels et al. 2001; Walzel et al. 2006 ).
Interestingly, there were no lectins that bound exclusively to naïve T cells. The lymphocytes also provide a reminder that cell binding events are not simply binary (Fig. 2B) . After normalizing fluorescent intensities to cell labeling efficiency, as assessed by flow cytometry, there are still significant variations in fluorescence intensity between cell types represented in our reductionist binary analysis. Overall, the lectin signatures across lymphocytes show fewer differences than the 24 human cell lines. The general similarity in surface glycan expression was to be expected as the cells share a common developmental lineage.
Using glycan signatures to predict E. coli tropism
To further explore the potential of the glycan signatures described above, an E. coli-mammalian cell-binding system was employed. E. coli bind to a variety of mammalian cells, such as the pathogenic E. coli strain K1, which binds to brain microvascular endothelial cells (BMEC) with high affinity (Kim 2006 ) and causes meningitis. Type 1 fimbriae based mannose specific E. coli binding is one of the major contributors for E. coli-mammalian cell binding (Teng et al. 2005) and the FimH subunit determines the mannose specific binding of type I fimbriae (Hung et al. 2002) . Clinically, human urinary tract and bladder infections caused by mannose specific E. coli-mammalian cell binding are treated with oral administration of mannose (Svanborg and Godaly 1997) .
The glycan signatures revealed that mannose-specific lectin binding is significantly different among different cell lines. For example, of the 16 mannose-specific lectins that bound to MCF7 only six bound to SkBr3. If such differences reflect a higher density of accessible mannose residues on MCF7 cells, the mannose-specific E. coli binding could be proportionally greater to those cells. To test this hypothesis, we performed E. coli-mammalian cell binding assays (Fig. 3A ) using three breast cancer cell lines MCF7, MDA-MB-231, and SkBr3, which bound to 16, 14, and 6 mannose-specific lectins, respectively. We calculated a mannose inhibition index of bacterial binding of wildtype K12 E. coli (WT) and the FimH knockout mutant (fimHΔ) by evaluating the ratio of bacterial binding (colony counts) in the presence and absence of soluble D-mannose (Fig. 3B) . The mannose inhibition index values of the WT for MCF7, MDA-MB-231 and SkBr3 are 0.48, 0.58 and 0.76, respectively, which are statistically different among these three cell lines (P<0.05) except MCF7 versus MDA-MB-231 (P=0.078). These ratios are inversely proportional to the number of the mannose-specific lectins bound to them. In contrast, the mannose inhibition index values of fimHΔ cells for MCF7, MDA-MB-231 and SkBr3 are 0.96, 1 and 1.03, respectively, which are close to 1 and not significantly different (P≥0.4). These results indicate that, as expected, the mannose-independent fimHΔ-mammalian cell binding is not inhibited by the addition of mannose. Taken together, the data indicate that the mannose specific E. coli-mammalian cell binding is predicted by the mannose-specific lectin chip binding. Thus, the glycan signatures can be used to predict bacterial tropisms for mammalian cells.
Biomarker discovery based on glycan signatures
To examine the power of the microarray platform for biomarker discovery, we analyzed lectin binding in a model cancer stem-like cell system by comparing the cell surface glycan signatures of all 24 cell types including MCF7 cells under standard and sphere culture conditions. Cancer (Fig. 1A marked by asterisks) . The lectins LEL, AAL and WGA showed the largest difference in fluorescent intensities. Each of these lectins effectively captured MCF7 cells but failed to capture MCF7 sphere cells (Fig. 4A) . The most significant difference was seen for LEL. This indicates that the LEL lectin may be used to distinguish these cancer cell subpopulations.
To demonstrate the usefulness of LEL as a potential biomarker, we looked for enhanced in vivo tumorigenicity in NOD/SCID mice injected with LEL-depleted MCF7 cells compared to those injected with regular MCF7 cells. A marked difference was seen in tumorigenicity between the two different groups (Fig. 4B, C) Recently, as proof-of-concept, lectin microarrays were used to capture selected glycosylation-defective cell lines (Tateno et al. 2007 ). We created a lectin microarray and exploited the ability of lectins to differentiate the accessible cell surface glycans on live human cells. We found a unique cell binding signature for each cell type analyzed. Additionally, we have shown that differentiation of immune cells with distinct biological characteristics show differential binding to the lectin microarray. Therefore, we not only present a high-throughput assessment of the accessible surface glycans of mammalian cells, but also demonstrate potential biological applications, including prediction of E. coli tropism and cancer stem cell biomarker discovery.
A key feature of infectious pathogens is their ability to directly and preferentially bind cell surface receptors via adhesins. The vast majority of adhesins are lectins, which recognize carbohydrate moieties on cell surfaces. For example, type I fimbriae expressed by various pathogenic strains of E. coli preferentially recognize mannose residues. As these residues are found on numerous glycoproteins, these types of interactions are not usually considered to be specific for a particular receptor. Interestingly, they appear to determine the tropism of a microorganism for a specific host tissue, due to preferential expression and/or accessibility of certain carbohydrate moieties in some tissues (Van Nhieu et al. 2005) . We successfully applied the glycan signatures generated in this study to predict E. coli mannose specific binding to mammalian cells. To our knowledge, this is the first example that reveals the potential use of lectin microarray cell profiling for the study of infectious pathogen tropism and pathogen-host interactions.
A major goal of high-throughput analyses can often relate to identification of novel biomarkers that have therapeutic and/or diagnostic values. We successfully identified novel and unique lectin binding patterns that can differentiate cancer stem-like cells in a model human breast cancer cell line. In vivo tumorigenicity experiments showed that indeed, these lectins could be used to enrich cancer stem-like cells. Thus, combined with other cancer stem cell enrichment methods, lectin microarray technology promises to be an important tool for identifying cell surface markers in tumors, and thus may facilitate therapies targeting cancer stem cells.
The current plant-based lectin microarray platform analyzes surface-accessible glycans that are often responsible for cell-cell or cell-pathogen interactions and have been shown to be targets of subtle variations (Gabius et al. 2004 ). While these have been very useful, we believe the addition of human and animal lectins will likely further empower the lectin microarray technology as they can reveal subtleties in the glycan structures on cell surfaces, which are their natural ligands. However, as evidenced by the biomarker study, even the current plant-based lectin microarrays are useful in 
Materials and Methods
Lectins and slides
Ninety-four lectins were collected from several sources listed in Supplementary 
Lectin microarray fabrication and quality control
Lectin proteins were resuspended in phosphate buffered saline (PBS) buffer with 0.02% Tween 20 and 25% glycerol to a final concentration of 1 μg/μl. Bovine serum albumin (BSA, 0.05 μg/μl) was also added to the buffer to improve spot morphology. The lectins were printed on different slides using the ChipWriter Pro (Bio-Rad) microarrayer. Three spots per lectin were printed in each block and 12 blocks were printed per slide. After printing, slides were covered with aluminum foil and stored at 4 o C for future use. To monitor the quality of the lectin microarrays, they were stained with 549 NHS Ester (DyLight) in 100-fold dilution at room temperature for 1 hour. The stained slides were washed twice with TBST followed by one wash with water. The dried slides were scanned with a GenePix 4100B (Axon) scanner at 10 μm Fig. 5 ). The scanning conditions were 600 mV laser power and 33%
PMT value at the Cy3 channel.
Culture of human cell lines and cell harvest
Twenty-three human cell lines and the sphere culture of MCF7 were collected (Supplementary Table II) . Suspension cells were collected with three PBS washes. Attached cells were dissociated enzymatically (0.05% trypsin in 0.5 mM EDTA (Invitrogen)) and mechanically by three PBS washes using a glass Pasteur pipette.
Cell probing, microarray scanning, and data extraction
Lectin microarrays were blocked for 1 hour at room temperature in 50 mM ethanolamine in 
In vitro Lymphocyte Activation
T cells isolated from C57BL/6 mice as described above were stimulated non-specifically using 2 ng/ml PMA and 400 ng/ml ionomycin in complete RPMI-1640 media supplemented with T cell growth factor. B cells isolated from C57BL/6 mice as described above were stimulated non-specifically using 100 ng/ml LPS in complete RPMI-1640 media supplemented with T cell growth factor (Mackensen et al. 1994 ). Allogeneic stimulation of T cells was achieved by culturing splenocytes from 2C TCR transgenic mice with irradiated splenocytes from Balb/c mice at a 1:1.4 ratio in RPMI-1640 complete media supplemented with T cell growth factor.
Lectin Flow Cytometry
Lectins were labeled with fluorescein-5-isothiocyanate 'Isomer-I' (Invitrogen) at 50 molar excess in PBS for 1 hour at room temperature. Excess free FITC was removed using PD-10
Sephadex Columns (GE Healthcare). Labeled lectins were concentrated with VivaSpin centrifugal concentrators (Sartorius AG). Lectin concentration was measured using a UV-visible spectrophotometer (Shimadzu Corp.). Staining with labeled lectins was performed at 4 o C for 1 hour with indicated concentrations of labeled lectin. Cells were washed with FACS wash buffer (PBS with 2% FCS and 0.05% Sodium Azide) prior to reading flow cytometry samples on FACSCalibur (BD Biosciences).
MCF7 sphere cell culture
Human breast cancer cell line MCF7 cells were obtained from ATCC (American Type Culture Collection). Cells were grown in DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen), in a 37 o C incubator containing 5% CO 2 . Sphere cell culture was performed according to published protocol with modifications (Dontu et al. 2003; Ponti et al. 2005) . Briefly, single cells were plated in ultralow attachment plates (Corning) at a density of 20,000 viable cells/ml in primary culture and 1000 cells/ml in passages. MCF7 sphere cells were grown in a serum-free mammary epithelial growth medium without bovine pituitary extract (MEGM, BioWhittaker), but supplemented with B27 (Invitrogen), 20 ng/ml EGF, and 20 ng/ml bFGF (BD Biosciences). In order to passage sphere cells (SP), spheres were collected into a 15-ml conical tube and allowed to settle for 15 minutes. Supernatant was removed. Sphere cells were dissociated enzymatically with 0.05% trypsin, 0.5 mM EDTA (Invitrogen) and mechanically by a glass Pasteur pipette. The cells obtained from dissociation were passed through a 40-μm sieve and analyzed microscopically for single cells and subjected to the following experiments.
Lectin staining and SP analysis
For SP analysis, cells were collected and resuspended in 37º C DMEM containing 2% FBS at 1x10 6 cells/ml. Hoechst 33342 cell staining was performed according to protocol originally developed by Goodell with slight modification (Goodell et al. 1996) . Briefly, the cells were 
E. coli-mammalian cell binding assay
Wild type E. coli strain K12 (CGSC strain#: 4401/ EMG2) and FimH mutant (fimhΔ) (CGSC strain#: 11068/ JW4283) were provided by the Yale E. coli Genetic Stock Center. The protocol was modified from Teng et al. (Teng et al. 2005) . Briefly, the freshly cultured cells were seeded to collagen-coated 24-well plates at ~200,000 cells/well and cultured at 37 o C, 5% CO 2 for about overnight, then adjusted OD 620 to 0.2 and incubated with or without 100 mM D-mannose at room temperature for 1 hr. Following the incubation period, 100 μl of the E. coli cells ( ~10 7 ) were added to each well of the 24-well plates with or without 100 mM D-mannose. The plates were incubated at 37 o C, 5% CO 2 for 90 minutes followed by two washes with FBS-free DMEM (4.5 g/L glucose) media and two washes with PBS to remove the unbound E. coli cells. The mammalian cells were disrupted to release the bound E. coli by treatment with 0.025% Triton X-100 at room temperature for 20 minutes. The suspensions were properly diluted and plated onto LB agar plate, followed by incubation at 37 o C overnight. The numbers of single colonies for each experiment were counted the next day.
LEL + Cell depletion and tumorigenicity assay
The M450 injections of β-estradiol (Sigma) dissolved in pure sesame oil (0.1 mg per 0.05 ml sesame oil per mouse) 1 day before tumor inoculation and at weekly intervals (Hardman et al. 1999; Kasukabe et al. 2005) . The enriched and control cells were injected into the same mouse into the upper right and left mammary pads, respectively, by using 22-gauge needles. An amount equivalent to 0.2 ml of cells was injected. Tumor growth was monitored thereafter. Five weeks after inoculation the mice were sacrificed, and the tumor tissues were analyzed by Hematoxylin and Eosin
staining (H & E).
Data analysis
To determine cell binding to lectin spots on the microarray, the local background intensity was subtracted from each lectin spot. A histogram of the subtracted background intensities for each microarray was plotted, centered on zero, and fitted to a normal distribution. Positive intensity (above background) appeared as a long tail in the histogram, representing a range of positive binding intensities (Supplementary Fig. 2) . If the intensity of a spot was 6 standard deviations (SD) above zero, it was scored positive.
For each lectin, the scores of the six replicate spots (duplicate microarrays and triplicate spots on each microarray) were used in a voting scheme to determine whether cells bound to that lectin. If more than 4 spots of a lectin were scored positive, it was defined as positive. Most of the lectins (80%) had either 0 or 6 spots scored positive (Supplementary Fig. 3 ).
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